Viridian Therapeutics

VRDN

Biotechnology · Healthcare

Also trades as: 0K1R.L

Price

$24.29

-0.21 (-0.86%)

Market Cap

$2.75B

Exchange

NASDAQ

Winston Score

Winston is serious

Below-average fundamentals — multiple weak pillars.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Mixed

Growth

Mixed

Cash Flow

Weak

Stability

Mixed

Valuation

Data not available

Track this stock — start free trial

Share count rising — dilution

+611.5% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 11.9M (2021) → 84.8M (2025)

Winston Score History

The full picture

Viridian Therapeutics is a biotechnology company that develops medicines for serious diseases caused by overactive immune systems. Its main focus is thyroid eye disease (TED), a condition where the immune system attacks tissue around the eyes, causing swelling and vision problems. The company's lead drug candidate, VRDN-001, targets a protein called IGF-1R, which plays a key role in driving TED.

Viridian makes money by developing and eventually selling prescription drugs, though it currently has no approved products generating meaningful revenue — the near-100% gross margin reflects minimal cost of goods on small research-related income. The company operates primarily in the United States and is in the clinical-stage phase, meaning it spends heavily on trials while earning little, which explains the deeply negative operating margin. Its main growth driver is winning regulatory approval for its TED treatments, but its biggest risk is competition from Amgen's already-approved teprotumumab (Tepezza), which dominates the TED market today.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+278.7% YoY

YoY Growth Rate

Strong revenue growth

EPS Growth

+14.6% YoY

YoY Growth Rate

Steady EPS growth

R&D Spend

$339M/ year

↑ Rising (+42% vs prior year)

478.4% of revenue

26.6x the sector average (18%)

Investing heavily in future products and technology

Insider Activity

18.0%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~13 months

$982M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Adequate runway but may need to raise capital within 2 years

Strong grower

Viridian Therapeutics is growing revenue at 279% year-over-year. The Winston Score penalises unprofitable companies, but revenue at this pace tells a different story — this is a company still in "build mode."

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

100.0%

Premium pricing power — 100.0% gross margin

Profit after running costs

Operating Margin

-44460.6%

Losing money on operations — -44460.6%

Return on the money invested

ROCE

-44.8%

Weak — -44.8% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

>+1,000%

Fast-growing sales (>+1,000% YoY)

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

3/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

-639.3%

Burning cash (-639.3%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.37

Conservative — low debt load (0.37)

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial